RU2004114865A - Композиция и способ лечения диабета - Google Patents
Композиция и способ лечения диабета Download PDFInfo
- Publication number
- RU2004114865A RU2004114865A RU2004114865/15A RU2004114865A RU2004114865A RU 2004114865 A RU2004114865 A RU 2004114865A RU 2004114865/15 A RU2004114865/15 A RU 2004114865/15A RU 2004114865 A RU2004114865 A RU 2004114865A RU 2004114865 A RU2004114865 A RU 2004114865A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- polypeptide
- medicament
- twice
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 4
- 206010012601 diabetes mellitus Diseases 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000007180 physiological regulation Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/474—Pancreatic thread protein; Reg protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4733—Acute pancreatitis-associated protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (8)
1. Фармацевтическая композиция, содержащая полипептид, имеющий пятнадцать аминокислот последовательности SEQ ID NO:3, с рН от 4 до 6.
2. Фармацевтическая композиция по п.1, где данная композиция представляет собой лиофилизированный порошок или раствор.
3. Фармацевтическая композиция по п.1, где композиция имеет рН от 4 до 5.
4. Фармацевтическая композиция по п.1, где полипептид находится в форме, выбранной из фармацевтически приемлемых сложных эфиров, солей и их смесей.
5. Фармацевтическая композиция по п.1, содержащая от 0,1 мг до 300 мг полипептида.
6. Применение фармацевтической композиции по п.1 для производства лекарственного средства для лечения диабета у человека или другого млекопитающего.
7. Применение фармацевтической композиции по п.1 для производства лекарственного средства для регенерации островков Лангерганса, бета клеток поджелудочной железы или установления нормальной физиологической регуляции уровня глюкозы у млекопитающего.
8. Применение фармацевтической композиции по п.6 или 7, где лекарственное средство вводится с частотой, выбранной из группы, состоящей из ежедневной, дважды в день, три раза в день, еженедельной, дважды в неделю, ежемесячной, непрерывной инфузии или их комбинаций.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32933001P | 2001-10-16 | 2001-10-16 | |
| US60/329,330 | 2001-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004114865A true RU2004114865A (ru) | 2005-05-27 |
Family
ID=23284879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004114865/15A RU2004114865A (ru) | 2001-10-16 | 2002-10-15 | Композиция и способ лечения диабета |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20040132644A1 (ru) |
| EP (1) | EP1435995A2 (ru) |
| JP (1) | JP2005506362A (ru) |
| KR (1) | KR20050036865A (ru) |
| CN (1) | CN1723034A (ru) |
| BR (1) | BR0213291A (ru) |
| CA (1) | CA2463769A1 (ru) |
| CO (2) | CO5570658A2 (ru) |
| CZ (1) | CZ2004479A3 (ru) |
| HU (1) | HUP0401612A3 (ru) |
| IL (1) | IL161073A0 (ru) |
| MA (1) | MA27503A1 (ru) |
| MX (1) | MXPA04003526A (ru) |
| NO (1) | NO20042012L (ru) |
| PE (1) | PE20030608A1 (ru) |
| PL (1) | PL370069A1 (ru) |
| RU (1) | RU2004114865A (ru) |
| SK (1) | SK1702004A3 (ru) |
| WO (1) | WO2003033808A2 (ru) |
| ZA (1) | ZA200402261B (ru) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004037277A2 (en) * | 2002-10-24 | 2004-05-06 | Mcgill University | Use of ingap for reversing diabetes |
| JP2008531730A (ja) * | 2005-03-04 | 2008-08-14 | キュアーディーエム、インク． | Ｉ型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物 |
| US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
| CA2726759C (en) * | 2005-05-25 | 2016-02-16 | Curedm Group Holdings, Llc | Human proislet peptide, derivatives and analogs thereof, and methods of using same |
| EP1840573A1 (en) * | 2006-03-27 | 2007-10-03 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
| US8785400B2 (en) * | 2006-11-22 | 2014-07-22 | Curedm Group Holdings, Llc | Methods and compositions relating to islet cell neogenesis |
| CN101896499B (zh) * | 2007-08-30 | 2014-02-12 | 库尔Dm股份有限公司 | 使用前胰岛肽及其类似物的组合物和方法 |
| AU2013323462A1 (en) * | 2012-09-27 | 2015-04-23 | Claresa LEVETAN | Generation of new pancreatic beta cells |
| US20160039877A1 (en) * | 2013-03-15 | 2016-02-11 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| CN104045699A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
| CN104045698B (zh) * | 2013-03-15 | 2019-04-16 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
| CN104045702A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
| CN103305457B (zh) * | 2013-06-06 | 2015-07-08 | 浙江省医学科学院 | 一种体外扩增胰岛β细胞的方法 |
| US20160039876A1 (en) * | 2014-03-28 | 2016-02-11 | Claresa Levetan | Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide |
| US10829527B2 (en) * | 2016-03-10 | 2020-11-10 | Shenzhen Hightide Biopharmaceutical, Ltd. | Conjugates of islet neogenesis peptides and analogs, and methods thereof |
| US20210196646A1 (en) * | 2018-08-15 | 2021-07-01 | Wake Forest University Health Sciences | Improved formulations for pancreatic islet encapsulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US127624A (en) * | 1872-06-04 | Improvement in apparatus for elevating water | ||
| US4658957A (en) * | 1985-01-28 | 1987-04-21 | Abbott Laboratories | Utility tray |
| US6106840A (en) * | 1988-06-23 | 2000-08-22 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
| US5834590A (en) * | 1995-02-22 | 1998-11-10 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Ingap protein involved in pancreatic islet neogenesis |
| DE69638315D1 (de) * | 1995-02-22 | 2011-02-17 | Eastern Virginia Med School | Ingap-protein und dessen beteiligung an der neogenese pankreatischer inselzellen |
| CN1152962C (zh) * | 1996-05-03 | 2004-06-09 | 艾博特公司 | 新型抗血管生成肽、其编码多核苷酸和抑制血管生成的方法 |
| US6090577A (en) * | 1997-05-22 | 2000-07-18 | Incyte Pharmaceuticals, Inc. | Disease associated acidic protein |
| US6986994B2 (en) * | 2001-01-09 | 2006-01-17 | Gmp Endotherapeutics, Inc. | INGAP displacement assays |
-
2002
- 2002-09-24 US US10/253,733 patent/US20040132644A1/en not_active Abandoned
- 2002-10-15 KR KR1020047005586A patent/KR20050036865A/ko not_active Ceased
- 2002-10-15 CA CA002463769A patent/CA2463769A1/en not_active Abandoned
- 2002-10-15 JP JP2003536523A patent/JP2005506362A/ja active Pending
- 2002-10-15 IL IL16107302A patent/IL161073A0/xx unknown
- 2002-10-15 WO PCT/US2002/032904 patent/WO2003033808A2/en not_active Ceased
- 2002-10-15 HU HU0401612A patent/HUP0401612A3/hu unknown
- 2002-10-15 EP EP02780465A patent/EP1435995A2/en not_active Ceased
- 2002-10-15 CZ CZ2004479A patent/CZ2004479A3/cs unknown
- 2002-10-15 PL PL02370069A patent/PL370069A1/xx not_active Application Discontinuation
- 2002-10-15 MX MXPA04003526A patent/MXPA04003526A/es unknown
- 2002-10-15 PE PE2002001014A patent/PE20030608A1/es not_active Application Discontinuation
- 2002-10-15 CN CNA028201922A patent/CN1723034A/zh active Pending
- 2002-10-15 RU RU2004114865/15A patent/RU2004114865A/ru not_active Application Discontinuation
- 2002-10-15 BR BR0213291-5A patent/BR0213291A/pt not_active IP Right Cessation
- 2002-10-15 SK SK170-2004A patent/SK1702004A3/sk not_active Application Discontinuation
-
2004
- 2004-03-23 ZA ZA200402261A patent/ZA200402261B/en unknown
- 2004-04-02 CO CO04031543A patent/CO5570658A2/es not_active Application Discontinuation
- 2004-04-09 MA MA27627A patent/MA27503A1/fr unknown
- 2004-05-14 NO NO20042012A patent/NO20042012L/no not_active Application Discontinuation
- 2004-06-25 CO CO04060289A patent/CO5590933A2/es not_active Application Discontinuation
-
2007
- 2007-12-04 US US11/999,208 patent/US20080171704A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040132644A1 (en) | 2004-07-08 |
| CA2463769A1 (en) | 2003-04-24 |
| ZA200402261B (en) | 2004-09-28 |
| BR0213291A (pt) | 2004-10-26 |
| US20080171704A1 (en) | 2008-07-17 |
| JP2005506362A (ja) | 2005-03-03 |
| SK1702004A3 (sk) | 2005-03-04 |
| PL370069A1 (en) | 2005-05-16 |
| HUP0401612A3 (en) | 2006-04-28 |
| IL161073A0 (en) | 2004-08-31 |
| CO5570658A2 (es) | 2005-10-31 |
| WO2003033808A3 (en) | 2003-09-18 |
| CZ2004479A3 (cs) | 2005-01-12 |
| PE20030608A1 (es) | 2003-08-26 |
| CN1723034A (zh) | 2006-01-18 |
| HUP0401612A2 (hu) | 2004-12-28 |
| CO5590933A2 (es) | 2005-12-30 |
| KR20050036865A (ko) | 2005-04-20 |
| MXPA04003526A (es) | 2004-07-22 |
| EP1435995A2 (en) | 2004-07-14 |
| NO20042012L (no) | 2004-07-16 |
| MA27503A1 (fr) | 2005-09-01 |
| WO2003033808A2 (en) | 2003-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004114865A (ru) | Композиция и способ лечения диабета | |
| CN102026666B (zh) | 促胰岛素肽缀合物制剂 | |
| US20130172250A1 (en) | Exendins To Lower Cholesterol And Triglycerides | |
| CN102718858A (zh) | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 | |
| US20120231022A1 (en) | Glp-1 receptor agonist compounds for sleep enhancement | |
| ES2316567T3 (es) | Adeponectina para la regeneracion hepatica. | |
| JP2003501361A5 (ru) | ||
| EP1808438A3 (en) | Purification and stabilization of peptide and proteins in pharmaceutical agents | |
| SE9301057L (sv) | Beredning med kontrollerad frisättning | |
| WO2001000223A2 (en) | Multiple agent diabetes therapy | |
| KR20090045416A (ko) | Ｈｇｈ를 포함하는 경구 전달용 제약 조성물 | |
| RU2008138561A (ru) | Фармацевтическая композиция, содержащая ghrp-6, для предотвращения и устранения фиброза и других патологических отложений в тканях | |
| CN102643339A (zh) | 一种glp-1类似物、制备方法及其应用 | |
| Kumar et al. | Controlled therapeutic trial to determine the optimum dose of antacids in duodenal ulcer. | |
| JP2533874B2 (ja) | ヒト成長ホルモンを用いる中毒個体の治療方法 | |
| WO2003061728B1 (en) | Oral administration of interferon-tau | |
| LU82013A1 (fr) | Nouvelles poudres lyophilisees contenant un sel de l'acide thiazolidine-4-carboxylique et leur procede de preparation | |
| US5700776A (en) | Medicaments comprising glicentin as active ingredient | |
| JP6328552B2 (ja) | Ｌ−アラニル−ｌ−グルタミンを有する蜂蜜組成物 | |
| CA2492378A1 (en) | Modified amino acid for the inhibition of platelet aggregation | |
| Stehouwer et al. | Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analogue octreotide (SMS 201-995) more effective than single therapy with either drug? | |
| JPH0347114A (ja) | 直腸及び膣適用に適する、生物学的に活性なペプチド薬剤を製造する方法 | |
| EP0459377A2 (en) | Use of E1 prostaglandin to cure male erectile inpotence | |
| JP2004508419A (ja) | 心電図のｑｔ間隔の短縮 | |
| RU2005140518A (ru) | Композиции и способы, включающие соединения гастрина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20060405 |